Hartl et al. recently reported the co-amplification of CEBPD and MYC in 25–85% of cancer patients (i.e., uterine carcinoma, hepatocellular carcinoma, breast invasive carcinoma, and prostate adenocarcinoma), but not that of CEBPB and MYC (0%) [16]. Here, CEBPB is linked to invasive breast carcinoma.